![]() |
产地 | China |
品牌 | Chemstan |
货号 | CSV03801 |
用途范围 | Research Grade |
纯度 | >95%% |
CAS编号 | 1393659-46-5 |
规格 | 100ug |
是否进口 | 否 |
Diridavumab, the alternative names CR6261, is a human monoclonal antibody direct against influenza A hemagglutinin. The CR6261 antibody was first discovered by the Scripps Institute and Crucell, a dutch biopharmaceutical company, and later developed by Janssen Pharmaceutical Companies of Johnson & Johnson under the trade name diridavumab. Cr6261 is under investigation in clinical trial NCT02016066 (A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of Diridavumab in Japanese Healthy Participants).
CSV03801
Homo sapiens
Influenza A virus
Liquid
0.01M PBS, pH 7.4.
1 mg/ml
>95% by SDS-PAGE.
Monoclonal
IgG1, lambda
Research Grade Diridavumab Biosimilar
HA,Hemagglutinin
Protein A or G purified from cell culture supernatant.
Please contact with the lab for this information.
Mammalian
P03455
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
CR-6261, CR6261, CAS: 1393659-46-5, Influenza Virus (Flu)
For research use only. Not suitable for clinical or therapeutic use.
15926423062
武汉科斯坦生物科技有限公司 版权所有(C)2023 XML 技术支持: 食品商务网 盖德化工网
武汉科斯坦生物科技有限公司